Jarosz Daniel
Chemical & Systems Biology, Stanford University School of Medicine, Stanford, California, USA; Developmental Biology, Stanford University School of Medicine, Stanford, California, USA.
Adv Cancer Res. 2016;129:225-47. doi: 10.1016/bs.acr.2015.11.001. Epub 2015 Nov 29.
Cancer cells have the unusual capacity to limit the cost of the mutation load that they harbor and simultaneously harness its evolutionary potential. This property fuels drug resistance, a key failure mode in oncogene-directed therapy. However, the factors that regulate this capacity might also provide an Achilles' heel that could be exploited therapeutically. Recently, insight has come from a seemingly distant field: protein folding. It is now clear that protein homeostasis broadly supports malignancy and fuels the rapid evolution of drug resistance. Among protein homeostatic mechanisms that influence cancer biology, the essential ATP-driven molecular chaperone heat-shock protein 90 (Hsp90) is especially important. Hsp90 catalyzes folding of many proteins that regulate growth and development. These "client" kinases, transcription factors, and ubiquitin ligases often play critical roles in human disease, especially cancer. Studies in a wide range of systems-from single-celled organisms to human tumor samples-suggest that Hsp90 can broadly reshape the map between genotype and phenotype, acting as a "capacitor" and "potentiator" of genetic variation. Indeed, it has likely done so to such a degree that it has left an impress on diverse genome sequences. Hsp90 can constitute as much as 5% of total protein in transformed cells and increased levels of heat-shock activation correlate with poor prognosis in breast cancer. These findings and others have motivated a flurry of interest in Hsp90 inhibitors as cancer therapeutics, which have met with rather limited success as single agents, but may eventually prove invaluable in limiting the emergence of resistance to other chemotherapeutics, both genotoxic and molecularly targeted. Here, we provide an overview of Hsp90 function, review its relationship to genetic variation and the evolution of new traits, and discuss the importance of these findings for cancer biology and future efforts to drug this pathway.
癌细胞具有一种特殊能力,既能限制其自身所携带突变负荷的代价,又能同时利用其进化潜力。这一特性助长了耐药性,而耐药性是致癌基因导向治疗中的一个关键失败模式。然而,调节这种能力的因素或许也会成为一个可被用于治疗的致命弱点。最近,从一个看似遥远的领域——蛋白质折叠中获得了相关见解。现在很清楚的是,蛋白质稳态在很大程度上支持恶性肿瘤,并助长耐药性的快速演变。在影响癌症生物学的蛋白质稳态机制中,至关重要的由ATP驱动的分子伴侣热休克蛋白90(Hsp90)尤为重要。Hsp90催化许多调节生长和发育的蛋白质的折叠。这些“客户”激酶、转录因子和泛素连接酶在人类疾病尤其是癌症中常常发挥关键作用。从单细胞生物到人类肿瘤样本等广泛系统中的研究表明,Hsp90能够广泛重塑基因型与表型之间的图谱,充当遗传变异的“电容器”和“增强器”。事实上,其作用程度可能已在多样的基因组序列上留下了印记。Hsp90在转化细胞中可占总蛋白的5%之多,热休克激活水平的升高与乳腺癌的不良预后相关。这些发现及其他研究激发了人们对Hsp90抑制剂作为癌症治疗药物的浓厚兴趣,这类抑制剂作为单一药物取得的成功相当有限,但最终可能在限制对其他化疗药物(包括基因毒性药物和分子靶向药物)产生耐药性方面证明具有极高价值。在此,我们概述了Hsp90的功能,回顾了其与遗传变异及新性状进化的关系,并讨论了这些发现对癌症生物学的重要性以及未来针对该途径研发药物的努力方向。